Phase I/Ⅱ Sturdy on Antiangiogenic Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer
Vascular endothelial growth factor receptor 1 and 2 (VEGFR1 andVEGFR2) are essential targets
to tumor angiogenesis, and we identified that peptides derived from these receptors
significantly induce the effective tumor specific CTL response in vitro and in vivo.
According to these findings, in this trial, we evaluate the safety, tolerability and immune
response of these peptide emulsified with Montanide ISA 51 in combination with gemcitabine
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
toxicities as assessed by NCI-CACAE ver3)
3 months
Yes
Mitsukazu Gotoh, M.D. & Ph.D
Study Chair
Fukushima Medical University, Department
Japan: Ministry of Health, Labor and Welfare
FPCR1R2-2
NCT00655785
September 2007
March 2013
Name | Location |
---|